OncRef

Clinical Trial: NCT04623775

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Bristol-Myers Squibb
Information Provided By:Bristol-Myers Squibb
Last Update Posted:2026-06-18

Study Overview

Brief Summary

The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves overall response rate (ORR) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC).

Official Title

A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Conditions

Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer

Intervention / Treatment

  • Biological: Nivolumab
  • Biological: Relatlimab
  • Drug: Carboplatin
  • Drug: Cisplatin
  • Drug: Paclitaxel
  • Drug: Nab-Paclitaxel
  • Drug: Pemetrexed

Other Study ID Numbers

  • CA224-104
  • 2020-004026-31
  • U1111-1256-8115

Start Date (Actual)

2021-02-17

Primary Completion Date (Actual)

2024-01-11

Study Completion Date (Actual)

2026-05-06

Enrollment (Actual)

468

Study Type

Interventional

Phase

Phase 2